Home » Topics » Regulatory » EMA

EMA
RSS

Akebia reaches agreement with FDA and EMA on phase III program for vadadustat

Oct. 7, 2015

EMA accepts Ultragenyx's MAA for aceneuramic acid prolonged release

Oct. 5, 2015

PTC Therapeutics submits variation for new indication in Europe for Translarna

Oct. 1, 2015

EMA committee recommends approval of Numient for Parkinson's disease

Sep. 29, 2015

European committee recommends approval of aflibercept for myopic CNV

Sep. 28, 2015

Amgen's Kyprolis and Blincyto receive positive opinions from EMA's CHMP

Sep. 28, 2015

EMA committee hands down positive opinion for Ravicti

Sep. 28, 2015

Exelixis' cobimetinib receives positive opinion from CHMP for treatment of melanoma

Sep. 28, 2015

CHMP adopts positive opinion on Gilead's Genvoya for HIV infection

Sep. 28, 2015

CHMP supports approval of Orkambi and expansion of Kalydeco indications

Sep. 28, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...